To further explore whether controlling CSN6-FASN axis can mitigate the tumor development in CRC patients, we established patient-derived xenografts (PDXs)44,45 by transplanting fresh primary CRC specimens into the NCG mice to analyze tumor growth (Fig. 7d). Here, COPS6 is linked to neoplasm.